vs
波士顿科学（MLSS）与Roivant Sciences Ltd.（ROIV）财务数据对比。点击上方公司名可切换其他公司
波士顿科学的季度营收约是Roivant Sciences Ltd.的1.0倍（$2.1M vs $2.0M），波士顿科学净利率更高（-53.0% vs -13301.2%，领先13248.2%），波士顿科学同比增速更快（2.2% vs -77.8%），过去两年波士顿科学的营收复合增速更高（-4.3% vs -73.7%）
波士顿科学公司是源自美国的跨国生物医疗企业，专业研发生产介入医疗领域医疗器械，产品覆盖介入放射学、介入心脏病学、外周介入治疗、神经调控、神经血管介入、电生理、心脏外科、血管外科、内镜、肿瘤学、泌尿与妇科等多个领域。
Roivant Sciences Ltd.是一家美国跨国医疗健康企业，2014年由维韦克·拉马斯瓦米创立，现任CEO为马特·格林。公司专注于将技术应用于药物研发领域，同时孵化运营多家生命科学与健康科技子公司，总部位于纽约，在波士顿、巴塞尔两大生物科技产业集群也设有核心办公点。
MLSS vs ROIV — 直观对比
营收规模更大
MLSS
是对方的1.0倍
$2.0M
营收增速更快
MLSS
高出80.0%
-77.8%
净利率更高
MLSS
高出13248.2%
-13301.2%
两年增速更快
MLSS
近两年复合增速
-73.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.1M | $2.0M |
| 净利润 | $-1.1M | $-265.9M |
| 毛利率 | 73.0% | — |
| 营业利润率 | -52.5% | -16966.1% |
| 净利率 | -53.0% | -13301.2% |
| 营收同比 | 2.2% | -77.8% |
| 净利润同比 | 46.4% | -257.0% |
| 每股收益（稀释后） | — | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLSSROIV
| Q4 25 | $2.1M | $2.0M | ||
| Q3 25 | $2.4M | $1.6M | ||
| Q2 25 | $2.3M | $2.2M | ||
| Q1 25 | $2.2M | $-39.6M | ||
| Q4 24 | $2.0M | $9.0M | ||
| Q3 24 | $2.5M | $4.5M | ||
| Q2 24 | $1.9M | $8.0M | ||
| Q1 24 | $2.2M | $28.9M |
净利润MLSSROIV
| Q4 25 | $-1.1M | $-265.9M | ||
| Q3 25 | $-1.2M | $-113.5M | ||
| Q2 25 | $-1.5M | $-223.4M | ||
| Q1 25 | $-2.0M | $-206.5M | ||
| Q4 24 | $-2.0M | $169.4M | ||
| Q3 24 | $-1.5M | $-230.2M | ||
| Q2 24 | $223.6K | $95.3M | ||
| Q1 24 | $-1.4M | $-151.1M |
毛利率MLSSROIV
| Q4 25 | 73.0% | — | ||
| Q3 25 | 69.5% | — | ||
| Q2 25 | 69.6% | — | ||
| Q1 25 | 73.8% | — | ||
| Q4 24 | 75.0% | — | ||
| Q3 24 | 73.0% | — | ||
| Q2 24 | 76.1% | — | ||
| Q1 24 | 74.5% | — |
营业利润率MLSSROIV
| Q4 25 | -52.5% | -16966.1% | ||
| Q3 25 | -48.1% | -19492.9% | ||
| Q2 25 | -63.9% | -13130.0% | ||
| Q1 25 | -89.5% | 674.8% | ||
| Q4 24 | -101.4% | -3042.6% | ||
| Q3 24 | -58.4% | -7636.0% | ||
| Q2 24 | -96.0% | -1279.5% | ||
| Q1 24 | -65.1% | -919.5% |
净利率MLSSROIV
| Q4 25 | -53.0% | -13301.2% | ||
| Q3 25 | -48.9% | -7225.9% | ||
| Q2 25 | -63.8% | -10292.9% | ||
| Q1 25 | -89.3% | 521.8% | ||
| Q4 24 | -101.1% | 1878.3% | ||
| Q3 24 | -58.1% | -5143.8% | ||
| Q2 24 | 12.1% | 1192.7% | ||
| Q1 24 | -64.1% | -522.3% |
每股收益（稀释后）MLSSROIV
| Q4 25 | — | $-0.38 | ||
| Q3 25 | $-0.01 | $-0.17 | ||
| Q2 25 | — | $-0.33 | ||
| Q1 25 | — | $-0.28 | ||
| Q4 24 | — | $0.23 | ||
| Q3 24 | $-0.02 | $-0.31 | ||
| Q2 24 | — | $0.12 | ||
| Q1 24 | — | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1M | $4.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.8M | $4.3B |
| 总资产 | $7.8M | $5.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MLSSROIV
| Q4 25 | $1.1M | $4.5B | ||
| Q3 25 | $1.3M | $4.4B | ||
| Q2 25 | $1.3M | $4.5B | ||
| Q1 25 | $2.2M | $4.9B | ||
| Q4 24 | $3.3M | $5.1B | ||
| Q3 24 | $4.8M | $5.4B | ||
| Q2 24 | $5.8M | $5.7B | ||
| Q1 24 | $5.0M | $6.5B |
总债务MLSSROIV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $311.7M | ||
| Q1 24 | — | $430.6M |
股东权益MLSSROIV
| Q4 25 | $2.8M | $4.3B | ||
| Q3 25 | $2.5M | $4.4B | ||
| Q2 25 | $3.3M | $4.3B | ||
| Q1 25 | $4.5M | $4.7B | ||
| Q4 24 | $5.8M | $5.2B | ||
| Q3 24 | $7.2M | $5.2B | ||
| Q2 24 | $8.0M | $5.4B | ||
| Q1 24 | $7.5M | $6.0B |
总资产MLSSROIV
| Q4 25 | $7.8M | $5.2B | ||
| Q3 25 | $8.5M | $5.1B | ||
| Q2 25 | $8.1M | $5.0B | ||
| Q1 25 | $9.1M | $5.4B | ||
| Q4 24 | $9.8M | $5.8B | ||
| Q3 24 | $11.2M | $6.2B | ||
| Q2 24 | $12.0M | $6.5B | ||
| Q1 24 | $11.4M | $7.2B |
负债/权益比MLSSROIV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | 0.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-226.1K | $-196.5M |
| 自由现金流经营现金流 - 资本支出 | — | $-201.4M |
| 自由现金流率自由现金流/营收 | — | -10076.0% |
| 资本支出强度资本支出/营收 | — | 246.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-776.7M |
8季度趋势，按日历期对齐
经营现金流MLSSROIV
| Q4 25 | $-226.1K | $-196.5M | ||
| Q3 25 | $81.8K | $-185.7M | ||
| Q2 25 | $-1.8M | $-204.4M | ||
| Q1 25 | $-1.0M | $-172.6M | ||
| Q4 24 | $-1.5M | $-207.3M | ||
| Q3 24 | $-973.9K | $-266.8M | ||
| Q2 24 | $783.7K | $-192.8M | ||
| Q1 24 | $-1.2M | $-108.5M |
自由现金流MLSSROIV
| Q4 25 | — | $-201.4M | ||
| Q3 25 | — | $-193.5M | ||
| Q2 25 | — | $-208.4M | ||
| Q1 25 | — | $-173.4M | ||
| Q4 24 | — | $-209.1M | ||
| Q3 24 | — | $-267.8M | ||
| Q2 24 | — | $-193.8M | ||
| Q1 24 | — | $-108.8M |
自由现金流率MLSSROIV
| Q4 25 | — | -10076.0% | ||
| Q3 25 | — | -12317.8% | ||
| Q2 25 | — | -9604.5% | ||
| Q1 25 | — | 438.1% | ||
| Q4 24 | — | -2318.5% | ||
| Q3 24 | — | -5984.4% | ||
| Q2 24 | — | -2425.5% | ||
| Q1 24 | — | -376.1% |
资本支出强度MLSSROIV
| Q4 25 | — | 246.9% | ||
| Q3 25 | — | 499.6% | ||
| Q2 25 | — | 185.9% | ||
| Q1 25 | — | -2.0% | ||
| Q4 24 | — | 20.3% | ||
| Q3 24 | — | 22.3% | ||
| Q2 24 | — | 12.1% | ||
| Q1 24 | — | 1.2% |
现金转化率MLSSROIV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -1.22× | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.50× | -2.02× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
